- Home
- ATNI vs FHTX Comparison
ATNI vs FHTX Comparison
Compare ATNI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNI | FHTX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.7M | 360.5M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATNI | FHTX |
|---|---|---|
| Price | $32.03 | $6.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 71.7K | ★ 209.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 34.29 | 25.32 |
| EPS | ★ 10.44 | N/A |
| Revenue | ★ $727,975,000.00 | $30,909,000.00 |
| Revenue This Year | $3.12 | $8.89 |
| Revenue Next Year | $1.10 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $13.86 | $3.27 |
| 52 Week High | $33.41 | $6.95 |
Technical Indicators
Market Signals| Indicator | ATNI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.25 | 71.68 |
| Support Level | $25.03 | $4.37 |
| Resistance Level | N/A | $6.76 |
| Average True Range (ATR) | 1.21 | 0.40 |
| MACD | 1.07 | 0.14 |
| Stochastic Oscillator | 82.44 | 85.53 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.